Curium acquires Eczacıbaşı-Monrol to expand Lu-177 capacity and PET network.
Curium, a nuclear medicine leader, is set to expand its Lu-177 capacity and PET footprint via an agreement to acquire Eczacıbaşı-Monrol. The acquisition will create a leading Lu-177 manufacturer, add 12 PET sites to Curium's network, and incorporate SPECT manufacturing capabilities and logistics infrastructure. This move aims to enhance patient reliability for diagnostic and therapeutic solutions.
April 08, 2024
3 Articles